Sarah Elizabeth Schellhorn, MD
Associate Professor of Medicine (Medical Oncology); Chief, Ambulatory Officer
Research & Publications
Biography
News
Research Summary
Dr. Schellhorn was lead investigator on a study called Breast Cancer Endocrine Therapy Adherence (known as BETA), which involves a daily text and a weekly check-in aimed at women who have hormone receptor-positive breast cancer. She is also part of several studies looking at health care management, health policy, and women's health. Some of her research also focuses on the care of elderly patients with breast cancer.
Extensive Research Description
Dr. Schellhorn was lead investigator on a study called Breast Cancer Endocrine Therapy Adherence (known as BETA), which involves a daily text and a weekly check-in aimed at women who have hormone receptor-positive breast cancer. She is also part of several studies looking at health care management, health policy, and women's health. Some of her research also focuses on the care of elderly patients with breast cancer.
Coauthors
Public Health Interests
Cancer; Health Care Management; Health Policy; Women's Health; Health Systems Reform
Selected Publications
- Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology MeetingsTalcott WJ, Chen K, Peters GW, Reddy KK, Weintraub SM, Mougalian SS, Adelson K, Evans SB. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 30-38. PMID: 35598798, PMCID: PMC9119957, DOI: 10.1016/j.ijrobp.2022.05.002.
- Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational StudyKalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, , Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer 2022, 8: e33859. PMID: 35588361, PMCID: PMC9164098, DOI: 10.2196/33859.
- Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice InitiativeMakhoul I, Anders M, Siegel R, Chiang A, Markham MJ, Chen RC, Mougalian S, Arnaoutakis K, Giuliani M, Im A, Kozlik MMP, Crist STS, Garrett-Mayer E, Kamal A. Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative. JCO Oncology Practice 2022, 18: e1209-e1218. PMID: 35467961, DOI: 10.1200/op.21.00807.
- Novel Tool to Monitor Adherence to Oral Oncolytics: A Pilot Study.Sun W, Reeve R, Ouellette T, Stutsky M, De Jesus R, Huffer MJ, Mougalian SS. Novel Tool to Monitor Adherence to Oral Oncolytics: A Pilot Study. JCO Clinical Cancer Informatics 2021, 5: 701-708. PMID: 34166064, DOI: 10.1200/cci.20.00151.
- Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United StatesMougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA. Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States. Advances In Therapy 2021, 38: 3487-3487. PMID: 33993427, DOI: 10.1007/s12325-021-01780-0.
- Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-AnalysisIbrahim EY, Domenicano I, Nyhan K, Elfil M, Mougalian SS, Cartmel B, Ehrlich BE. Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis. Frontiers In Oncology 2021, 11: 642382. PMID: 33996556, PMCID: PMC8121254, DOI: 10.3389/fonc.2021.642382.
- Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United StatesMougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA. Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States. Advances In Therapy 2021, 38: 2226-2228. PMID: 33826091, PMCID: PMC8107069, DOI: 10.1007/s12325-021-01683-0.
- Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapyRozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.
- Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United StatesMougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States. Advances In Therapy 2021, 38: 2213-2225. PMID: 33491157, PMCID: PMC8107067, DOI: 10.1007/s12325-020-01613-6.
- Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast CancerKunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.
- Response to Meurs, Menke-Pluijmers, Seisling, and WestenendWang SY, Hung P, Killelea BK, Mougalian SS, Evans SB, Gross CP. Response to Meurs, Menke-Pluijmers, Seisling, and Westenend. JNCI Cancer Spectrum 2020, 4: pkaa080. PMID: 33417658, PMCID: PMC7771427, DOI: 10.1093/jncics/pkaa080.
- Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast CancerPusztai L, Taylor R, Mougalian SS. Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer. Cancer Cell 2020, 38: 323-325. PMID: 32931742, DOI: 10.1016/j.ccell.2020.08.006.
- Patient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway DevelopmentSchulman-Green D, Cherlin E, Capasso R, Mougalian SS, Wang S, Gross CP, Bajaj PS, Eakle K, Patel S, Douglas K, Adelson K. Patient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway Development. The Patient - Patient-Centered Outcomes Research 2020, 13: 683-697. PMID: 32508006, DOI: 10.1007/s40271-020-00426-7.
- Long term outcomes of sentinel lymph node biopsy for ductal carcinoma in situHung P, Wang SY, Killelea BK, Mougalian SS, Evans SB, Sedghi T, Gross CP. Long term outcomes of sentinel lymph node biopsy for ductal carcinoma in situ. JNCI Cancer Spectrum 2019, 3: pkz052. PMID: 32337481, PMCID: PMC7049982, DOI: 10.1093/jncics/pkz052.